19 June 2013
Keywords: roche, actemra, impresses, ra, study, swiss, drug
Article | 13 August 2007
Swiss drug major Roche says that its developmental rheumatoid arthritis treatment Actemra (tocilizumab) met its primary safety and efficacy
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 August 2007
20 August 2007
18 June 2013
© 2013 thepharmaletter.com